Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Biocure Technology

CNSX:CURE
Snowflake Description

Slightly overvalued with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CURE
CNSX
CA$31M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Biocure Technology Inc. develops and commercializes biopharmaceutical technologies for uses in recombinant and ranibizumab in South Korea. The last earnings update was 81 days ago. More info.


Add to Portfolio Compare Print
  • Biocure Technology has significant price volatility in the past 3 months.
CURE Share Price and Events
7 Day Returns
3.2%
CNSX:CURE
-1.2%
CA Biotechs
0.6%
CA Market
1 Year Returns
-20%
CNSX:CURE
-37%
CA Biotechs
5.8%
CA Market
CURE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biocure Technology (CURE) 3.2% 18.5% 60% -20% - -
CA Biotechs -1.2% 2.9% 103.9% -37% 58% 14.4%
CA Market 0.6% 0.5% 3.6% 5.8% 5% 14%
1 Year Return vs Industry and Market
  • CURE outperformed the Biotechs industry which returned -37% over the past year.
  • CURE underperformed the Market in Canada which returned 5.8% over the past year.
Price Volatility
CURE
Industry
5yr Volatility vs Market

CURE Value

 Is Biocure Technology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biocure Technology to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biocure Technology.

CNSX:CURE Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Extrapolated from most recent financials. See below
Discount Rate (Cost of Equity) See below 8.5%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:CURE
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.37
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.373 (1 + (1- 26.5%) (7.77%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.44% + (1.303 * 5.44%)
8.53%

Discounted Cash Flow Calculation for CNSX:CURE using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biocure Technology is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:CURE DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 8.53%)
2020 15.03 Est @ 50.73% 13.85
2021 20.43 Est @ 35.94% 17.35
2022 25.66 Est @ 25.59% 20.08
2023 30.37 Est @ 18.35% 21.90
2024 34.40 Est @ 13.27% 22.85
2025 37.75 Est @ 9.72% 23.11
2026 40.48 Est @ 7.24% 22.83
2027 42.71 Est @ 5.5% 22.19
2028 44.54 Est @ 4.28% 21.33
2029 46.06 Est @ 3.43% 20.33
Present value of next 10 years cash flows CA$205.00
CNSX:CURE DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CA$46.06 × (1 + 1.44%) ÷ (8.53% – 1.44%)
CA$659.46
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$659.46 ÷ (1 + 8.53%)10
CA$290.98
CNSX:CURE Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$205.00 + CA$290.98
CA$495.98
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$495.98 / 97.13
CA$5.11
CNSX:CURE Discount to Share Price
Calculation Result
Value per share (CAD) From above. CA$5.11
Current discount Discount to share price of CA$0.32
= -1 x (CA$0.32 - CA$5.11) / CA$5.11
93.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Biocure Technology is available for.
Intrinsic value
>50%
Share price is CA$0.32 vs Future cash flow value of CA$5.11
Current Discount Checks
For Biocure Technology to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Biocure Technology's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Biocure Technology's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biocure Technology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biocure Technology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:CURE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in CAD CA$-0.05
CNSX:CURE Share Price ** CNSX (2020-02-14) in CAD CA$0.32
North America Biotechs Industry PE Ratio Median Figure of 36 Publicly-Listed Biotechs Companies 19.15x
Canada Market PE Ratio Median Figure of 511 Publicly-Listed Companies 15.94x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biocure Technology.

CNSX:CURE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:CURE Share Price ÷ EPS (both in CAD)

= 0.32 ÷ -0.05

-7.07x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocure Technology is loss making, we can't compare its value to the North America Biotechs industry average.
  • Biocure Technology is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Biocure Technology's expected growth come at a high price?
Raw Data
CNSX:CURE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.07x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Biotechs Industry PEG Ratio Median Figure of 33 Publicly-Listed Biotechs Companies 1.2x
Canada Market PEG Ratio Median Figure of 248 Publicly-Listed Companies 1.13x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biocure Technology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biocure Technology's assets?
Raw Data
CNSX:CURE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in CAD CA$0.01
CNSX:CURE Share Price * CNSX (2020-02-14) in CAD CA$0.32
Canada Biotechs Industry PB Ratio Median Figure of 31 Publicly-Listed Biotechs Companies 3.71x
Canada Market PB Ratio Median Figure of 2,341 Publicly-Listed Companies 1.38x
CNSX:CURE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:CURE Share Price ÷ Book Value per Share (both in CAD)

= 0.32 ÷ 0.01

29.02x

* Primary Listing of Biocure Technology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biocure Technology is overvalued based on assets compared to the CA Biotechs industry average.
X
Value checks
We assess Biocure Technology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biocure Technology has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CURE Future Performance

 How is Biocure Technology expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Biocure Technology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
36.1%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biocure Technology expected to grow at an attractive rate?
  • Unable to compare Biocure Technology's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Biocure Technology's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Biocure Technology's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:CURE Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 36.1%
Canada Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 58.4%
Canada Market Earnings Growth Rate Market Cap Weighted Average 10.4%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:CURE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:CURE Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-09-30 0 -2 -4
2019-06-30 0 -2 -4
2019-03-31 -3 -6
2018-12-31 -3 -7
2018-09-30 0 -3 -9
2018-06-30 0 -3 -9
2018-03-31 0 -3 -5
2017-12-31 -2 -5
2017-09-30 0 -2 -3
2017-06-30 0 -1 -3
2017-03-31 0 -1 -2
2016-12-31 0 -1 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Biocure Technology is high growth as no earnings estimate data is available.
  • Unable to determine if Biocure Technology is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:CURE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Biocure Technology Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CURE Past Financials Data
Date (Data in CAD Millions) EPS *
2019-09-30 -0.05
2019-06-30 -0.04
2019-03-31 -0.06
2018-12-31 -0.07
2018-09-30 -0.09
2018-06-30 -0.09
2018-03-31 -0.06
2017-12-31 -0.06
2017-09-30 -0.02
2017-06-30 -0.82
2017-03-31 -0.03
2016-12-31 -0.03

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Biocure Technology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Biocure Technology's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Biocure Technology's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Biocure Technology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biocure Technology has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CURE Past Performance

  How has Biocure Technology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biocure Technology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biocure Technology does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Biocure Technology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biocure Technology's 1-year growth to the North America Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biocure Technology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biocure Technology Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:CURE Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 -0.07 -4.39 3.23 0.75
2019-06-30 0.00 -4.16 3.23 0.65
2019-03-31 -6.14 4.88 0.93
2018-12-31 -6.59 4.95 1.36
2018-09-30 0.07 -8.56 4.57 0.95
2018-06-30 -0.01 -8.51 4.34 1.09
2018-03-31 -0.01 -5.49 1.26 0.83
2017-12-31 -4.78 1.07 0.30
2017-09-30 0.01 -2.87 0.70 0.67
2017-06-30 0.01 -2.86 0.71 0.50
2017-03-31 0.01 -2.17 0.65 0.40
2016-12-31 0.01 -2.02 0.65 0.32
2015-12-31 -1.21 0.48 0.45

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biocure Technology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biocure Technology has efficiently used its assets last year compared to the North America Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biocure Technology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biocure Technology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biocure Technology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CURE Health

 How is Biocure Technology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biocure Technology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biocure Technology's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Biocure Technology's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Biocure Technology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biocure Technology Company Filings, last reported 4 months ago.

CNSX:CURE Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 1.07 2.42 0.10
2019-06-30 1.00 2.17 0.00
2019-03-31 1.48 1.69 0.17
2018-12-31 0.90 1.74 0.11
2018-09-30 2.19 0.86 0.20
2018-06-30 2.23 0.87 0.42
2018-03-31 2.31 0.49 0.42
2017-12-31 2.88 0.47 1.08
2017-09-30 0.61 1.35 1.89
2017-06-30 1.13 1.38 2.56
2017-03-31 -0.28 1.02 0.86
2016-12-31 -0.28 1.02 0.86
2015-12-31 -2.58 1.93 0.01
  • Biocure Technology's level of debt (226%) compared to net worth is high (greater than 40%).
  • Unable to establish if Biocure Technology's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Biocure Technology has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Biocure Technology has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Biocure Technology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biocure Technology has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CURE Dividends

 What is Biocure Technology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biocure Technology dividends.
If you bought CA$2,000 of Biocure Technology shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biocure Technology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biocure Technology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:CURE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 63 Stocks 2.1%
Canada Market Average Dividend Yield Market Cap Weighted Average of 336 Stocks 3.4%
Canada Minimum Threshold Dividend Yield 10th Percentile 1%
Canada Bottom 25% Dividend Yield 25th Percentile 1.9%
Canada Top 25% Dividend Yield 75th Percentile 5.3%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biocure Technology has not reported any payouts.
  • Unable to verify if Biocure Technology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biocure Technology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biocure Technology has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Biocure Technology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biocure Technology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biocure Technology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CURE Management

 What is the CEO of Biocure Technology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sang Lee
AGE 53
TENURE AS CEO 2.3 years
CEO Bio

Dr. Sang-Mok Lee serves as President and Chief Executive Officer of Biocurepharm, Inc. since November 24, 2017. Dr. Lee has been the President and Chief Executive Officer of the Biocurepharm Corporation in Korea, since its inception in 2005. He has been Director of Biocurepharm, Inc. since June 21, 2017. Dr. Lee has been a Director of Gravis Energy Corp. since June 21, 2017. He is an adjunct professor in microbiology at Chungnam National University. Dr. Lee is a committee member for the hi-tech medical complex city in Daejeon, Korea and a committee member of KOFST (the Korean Federation of Science and Technology Societies). Dr. Lee holds a PhD in microbiology from Busan National University in Korea.

CEO Compensation
  • Insufficient data for Sang to compare compensation growth.
  • Insufficient data for Sang to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure of the Biocure Technology management team in years:

1.9
Average Tenure
  • The average tenure for the Biocure Technology management team is less than 2 years, this suggests a new team.
Management Team

Sang Lee

TITLE
President
AGE
53
TENURE
2.3 yrs

Konstantin Lichtenwald

TITLE
CFO, Corporate Secretary & Director
TENURE
1.9 yrs

Marco Nonni

TITLE
Consultant
TENURE
1.4 yrs
Board of Directors Tenure

Average tenure of the Biocure Technology board of directors in years:

2
Average Tenure
  • The average tenure for the Biocure Technology board of directors is less than 3 years, this suggests a new board.
Board of Directors

Konstantin Lichtenwald

TITLE
CFO, Corporate Secretary & Director
TENURE
1.9 yrs

Collin Kim

TITLE
Independent Director
AGE
53
TENURE
4.5 yrs

Sang Lee

TITLE
President
AGE
53
TENURE
2.7 yrs

Jae Shin

TITLE
Member of Advisory Board
TENURE
2 yrs

Hyun Lee

TITLE
Member of Advisory Board
TENURE
2 yrs

Heon Lee

TITLE
Member of Advisory Board
TENURE
2 yrs

Hans Frykman

TITLE
Director
TENURE
1.4 yrs

Danny Joh

TITLE
Independent Director
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
X
Management checks
We assess Biocure Technology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biocure Technology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CURE News

Simply Wall St News

Did Changing Sentiment Drive Biocure Technology's (CNSX:CURE) Share Price Down A Worrying 63%?

Biocure Technology may have better days ahead, of course; we've only looked at a one year period. … View our latest analysis for Biocure Technology We don't think Biocure Technology's revenue of CA$69,287 is enough to establish significant demand. … But since the share price has dived -63% in the last year, it looks like some investors think it's time to abandon ship, so to speak.

Simply Wall St -

How Much Of Biocure Technology Inc. (CNSX:CURE) Do Insiders Own?

The big shareholder groups in Biocure Technology Inc. … With a market capitalization of CA$47m, Biocure Technology is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for Biocure Technology

Simply Wall St -

Should You Be Concerned About Biocure Technology Inc's (CNSX:CURE) Investors?

I am going to take a deep dive into Biocure Technology Inc’s (CNSX:CURE) most recent ownership structure, not a frequent subject of discussion among individual investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Differences in ownership structure of companies can have a profound effect on how management's incentives are aligned with shareholder returns, and whether they adhere to corporate governance best practices.

Simply Wall St -

CURE Company Info

Description

Biocure Technology Inc. develops and commercializes biopharmaceutical technologies for uses in recombinant and ranibizumab in South Korea. The company is developing Interferons- ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing CAR T Cell Therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; a hair growth production product; and a breast cancer detection kit. Biocure Technology Inc. is headquartered in Vancouver, Canada.

Details
Name: Biocure Technology Inc.
CURE
Exchange: CNSX
Founded:
CA$31,080,930
97,127,908
Website: http://www.biocuretech.com
Address: Biocure Technology Inc.
1055 West Hastings Street,
Suite 300,
Vancouver,
British Columbia, V6E 2E9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX CURE Common Shares Canadian National Stock Exchange CA CAD 27. Nov 2017
OTCPK BICT.F Common Shares Pink Sheets LLC US USD 27. Nov 2017
Number of employees
Current staff
Staff numbers
0
Biocure Technology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/02/18 01:19
End of day share price update: 2020/02/14 00:00
Last earnings filing: 2019/11/29
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.